

Contact Carl Berke For More Information [Carl@Berkeseearch.com](mailto:Carl@Berkeseearch.com)

- **04.14.23 - Epic Sciences Raises \$24M in Series G Financing to Continue Funding Commercialization of DefineMBC (PR)**
  - Epic Sciences is a privately held diagnostics company, has completed a \$24 million Series G which together with its \$43 million Series F financing, totals \$67 million raised in the last twelve months. The company will use the capital from this additional round of private investment to fund the commercial infrastructure required to commercialize the three component tests of DefineMBC, which together provide a comprehensive blood-based biopsy result for patients with metastatic breast cancer. The investment was co-led by Deerfield Management and Arsenal Capital Partners, and included broad participation from the company's shareholders including Blue Ox Healthcare Partners, Domain Ventures, and Labcorp.
- **04.14.23 - TORL BioTherapeutics Launches with \$158 Million Series B Financing to Advance Development of Novel Oncology Biologics (medtechalert)**
  - TORL BioTherapeutics, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a \$158 million Series B financing. TORL's pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) was discovered in the laboratory of scientific co-founder Dennis Slamon, M.D., Ph.D., Professor of Medicine, and Chief of the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine (DGSOM). He is an accomplished physician and scientist whose research was pivotal in identifying HER2 as a target in breast cancer and the development and initial approval of trastuzumab (Herceptin). Dr. Slamon's lab went on to discover CDK4/6 as an important target in hormone receptor (HR+) positive breast cancer. Subsequently, his group led the clinical development of CDK4/6 inhibitors, resulting in breakthrough status therapies palbociclib (Ibrance) and ribociclib (Kisqali), in HR+ breast cancer.
- **04.14.23 - Samsung Biologics invests in Swiss ADC firm (bioprocessintl)**
  - Samsung Venture Investment Corporation has invested an undisclosed amount in Araris Biotech ahead of a series A funding round. The investment was made by Samsung Life Science Fund, a joint creation between Samsung Biologics and trading company Samsung C&T, which is managed by Samsung Ventures Investment Corporation (Samsung Ventures), an investment corporation that aims to promote the advancement of technologies. According to Araris, the funding will be used to support future advancement of potential candidates for ADCs. Moreover, The Korea Herald reported that Samsung Biologics aims to increase its ADC portfolio and actively participate in the manufacture of ADC drugs facilitated by the collaboration with Araris.
- **04.13.23 - Novo Holdings Invests in US\$105 Million Series C Funding of Alentis Therapeutics (medtechalert)**
  - \$105 million Series C financing of Alentis Therapeutics, a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors. The financing will support clinical development of Alentis' lead investigational products ALE.F02 and ALE.C04 as well as the CLDN1 platform development. The funding round was led by Jeito Capital together with Novo Holdings A/S and RA Capital Management and participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio Fund 2, and Schroders Capital.
- **04.13.23 - Aer Therapeutics Closes \$36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases (PR)**
  - Funding was received from a syndicate of premier life science industry investors, including Canaan, OrbiMed, and Hatteras Venture Partners. Proceeds from the financing will be used to advance the development of AER-01, the company's novel inhaled small molecule mucolytic drug designed to liquefy mucus plugs in the lungs of patients with chronic obstructive pulmonary disease (COPD). Aer Therapeutics plans to initiate a first-in-human Phase 1 clinical trial of AER-01 in mid-2023. Aer is a spinout from Dr. John Fahy's laboratory UCSF. Dr. Fahy's laboratory collaboratively developed AER-01 with Stefan Oscarson's glycochemistry laboratory at University College Dublin (UCD) and Anne Marie Healy's pharmaceutical technology laboratory at Trinity College Dublin (TCD). The combined expertise of these laboratories in mucus biology, glycochemistry, inhaled drug formulation, drug delivery, and lung imaging, supported by a development grant from the National Institutes of Health, underlies the novel AER-01 technology. As part of the Series A financing, the company has expanded its board of directors to include new appointees: Tim Shannon, M.D., general partner at Canaan; Rishi Gupta, J.D., partner at OrbiMed; Christy Shaffer, Ph.D., general partner at Hatteras Venture Partners; and, Thomas Mathers, CEO at Allievex. They join current board members Mr. Shaffer and Dr. Fahy.
- **04.11.23 - ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY \$8.7 MILLION (PR)**
  - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that in the last week it has raised aggregate gross proceeds of approximately \$8.7 million between its now-terminated at-the-market program and a private placement to individual members of its Board of Directors and management. As previously disclosed, on March 31, 2023, the Company entered into an At-The-Market (ATM) Equity Offering Sales Agreement (SM) with BofA Securities, Inc. ("BofA") and ThinkEquity LLC. On April 4, 2023, the Company sold 704,000 shares of its common stock pursuant to the ATM Sales Agreement at a price of \$10.88 per share, for gross proceeds of approximately \$7.66 million. Following the sale, the Company terminated the ATM Sales Agreement effective April 9, 2023.
-